Display Settings:

Format

Send to:

Choose Destination

    Diabetes Care. 2009 Apr;32(4):600-2. Epub 2009 Jan 8.

    Incremental value of the pancreas allograft to the survival of simultaneous pancreas-kidney transplant recipients.

    Salvalaggio PR, Dzebisashvili N, Pinsky B, Schnitzler MA, Burroughs TE, Graff R, Axelrod DA, Brennan DC, Lentine KL.

    Center for Outcomes Research, Saint Louis University School of Medicine, St. Louis, Missouri, USA. psalvala@u.washington.edu

    OBJECTIVE: To quantify the incremental survival benefit of the pancreas allograft in simultaneous pancreas-kidney (SPK) transplant recipients. RESEARCH DESIGN AND METHODS: Data from the national transplant database from 2000 to 2007 were analyzed. SPK recipients who had functioning allografts to 1-year post transplant (n = 3,304) were compared with those who had failure of the renal (n = 233) or pancreatic (n = 112) graft. The main outcome was a projection of 10 life-years of patient survival beyond the first transplant anniversary. RESULTS: Recipients with function of both organs accrued 9.4 life-years following transplantation. Projected survival in patients with kidney failure was reduced to 2.5 life-years. Pancreas failure reduced predicted survival to 8 life-years. Renal allograft failure impacts life expectancy significantly (adjusted hazard ratio [aHR] 12.13). However, pancreas allograft failure was also associated with reduced survival (aHR 2.62). CONCLUSIONS: Although the majority of the survival benefit of SPK transplant is due to the renal transplant, pancreas allograft function does contribute to patient survival.

    PMID: 19131460 [PubMed - indexed for MEDLINE]

    PMCID: 2660461

    Supplemental Content

    Click here to read